These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 31366440)

  • 21. [The incidence and risk factors for heterogeneous vancomycin intermediate Staphylococcus aureus].
    Feng NN; Wang Q; Song YL; He LX; Zhou CM; Xie HM; Li HY
    Zhonghua Nei Ke Za Zhi; 2013 Apr; 52(4):318-22. PubMed ID: 23925360
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evolution of multidrug resistance during Staphylococcus aureus infection involves mutation of the essential two component regulator WalKR.
    Howden BP; McEvoy CR; Allen DL; Chua K; Gao W; Harrison PF; Bell J; Coombs G; Bennett-Wood V; Porter JL; Robins-Browne R; Davies JK; Seemann T; Stinear TP
    PLoS Pathog; 2011 Nov; 7(11):e1002359. PubMed ID: 22102812
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of heterogeneous vancomycin-intermediate resistance, MIC and accessory gene regulator (agr) dysfunction among clinical bloodstream isolates of staphyloccocus aureus.
    Harigaya Y; Ngo D; Lesse AJ; Huang V; Tsuji BT
    BMC Infect Dis; 2011 Oct; 11():287. PubMed ID: 22026752
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Prevalence of Vancomycin-Intermediate Staphylococcus aureus and Heterogeneous VISA Among Methicillin-Resistant Strains Isolated from Pediatric Population in a Turkish University Hospital.
    Mirza HC; Sancak B; Gür D
    Microb Drug Resist; 2015 Oct; 21(5):537-44. PubMed ID: 25919019
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
    Cui L; Neoh HM; Shoji M; Hiramatsu K
    Antimicrob Agents Chemother; 2009 Mar; 53(3):1231-4. PubMed ID: 19124662
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reduced vancomycin susceptibility and increased macrophage survival in Staphylococcus aureus strains sequentially isolated from a bacteraemic patient during a short course of antibiotic therapy.
    Basco MDS; Kothari A; McKinzie PB; Revollo JR; Agnihothram S; Azevedo MP; Saccente M; Hart ME
    J Med Microbiol; 2019 Jun; 68(6):848-859. PubMed ID: 31136294
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detection of intermediately vancomycin-susceptible and heterogeneous Staphylococcus aureus isolates: comparison of Etest and Agar screening methods.
    Riederer K; Shemes S; Chase P; Musta A; Mar A; Khatib R
    J Clin Microbiol; 2011 Jun; 49(6):2147-50. PubMed ID: 21490190
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduced susceptibility to vancomycin in isogenic Staphylococcus aureus strains of sequence type 59: tracking evolution and identifying mutations by whole-genome sequencing.
    Chen CJ; Lin MH; Shu JC; Lu JJ
    J Antimicrob Chemother; 2014 Feb; 69(2):349-54. PubMed ID: 24092658
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The evolution of vancomycin intermediate Staphylococcus aureus (VISA) and heterogenous-VISA.
    Howden BP; Peleg AY; Stinear TP
    Infect Genet Evol; 2014 Jan; 21():575-82. PubMed ID: 23567819
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical and Microbiological Characteristics of Heteroresistant and Vancomycin-Intermediate Staphylococcus aureus from Bloodstream Infections in a Brazilian Teaching Hospital.
    da Costa TM; Morgado PG; Cavalcante FS; Damasco AP; Nouér SA; Dos Santos KR
    PLoS One; 2016; 11(8):e0160506. PubMed ID: 27575698
    [TBL] [Abstract][Full Text] [Related]  

  • 31. walK and clpP mutations confer reduced vancomycin susceptibility in Staphylococcus aureus.
    Shoji M; Cui L; Iizuka R; Komoto A; Neoh HM; Watanabe Y; Hishinuma T; Hiramatsu K
    Antimicrob Agents Chemother; 2011 Aug; 55(8):3870-81. PubMed ID: 21628539
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance.
    Neoh HM; Cui L; Yuzawa H; Takeuchi F; Matsuo M; Hiramatsu K
    Antimicrob Agents Chemother; 2008 Jan; 52(1):45-53. PubMed ID: 17954695
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of the Etest GRD for the detection of Staphylococcus aureus with reduced susceptibility to glycopeptides.
    Leonard SN; Rossi KL; Newton KL; Rybak MJ
    J Antimicrob Chemother; 2009 Mar; 63(3):489-92. PubMed ID: 19136530
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of rpoB mutations on reduced vancomycin susceptibility in Staphylococcus aureus.
    Watanabe Y; Cui L; Katayama Y; Kozue K; Hiramatsu K
    J Clin Microbiol; 2011 Jul; 49(7):2680-4. PubMed ID: 21525224
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative proteomics-based identification of genes associated with glycopeptide resistance in clinically derived heterogeneous vancomycin-intermediate Staphylococcus aureus strains.
    Chen H; Liu Y; Zhao C; Xiao D; Zhang J; Zhang F; Chen M; Wang H
    PLoS One; 2013; 8(6):e66880. PubMed ID: 23840544
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure.
    Kelley PG; Gao W; Ward PB; Howden BP
    J Antimicrob Chemother; 2011 May; 66(5):1057-60. PubMed ID: 21393156
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence of vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA among methicillin-resistant S. aureus with high vancomycin minimal inhibitory concentrations in Taiwan: A multicenter surveillance study, 2012-2013.
    Huang SH; Chen YC; Chuang YC; Chiu SK; Fung CP; Lu PL; Wang LS; Wu TL; Wang JT
    J Microbiol Immunol Infect; 2016 Oct; 49(5):701-707. PubMed ID: 26320398
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical outcomes and molecular typing of heterogenous vancomycin-intermediate Staphylococcus aureus bacteremia in patients in intensive care units.
    Hu HC; Kao KC; Chiu LC; Chang CH; Hung CY; Li LF; Liu TP; Lin LC; Chen NH; Huang CC; Yang CT; Lu JJ
    BMC Infect Dis; 2015 Oct; 15():444. PubMed ID: 26497595
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection of vancomycin nonsusceptible strains in clinical isolates of Staphylococcus aureus in northern Iran.
    Asadpour L; Ghazanfari N
    Int Microbiol; 2019 Dec; 22(4):411-417. PubMed ID: 30811005
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A mutation of RNA polymerase β' subunit (RpoC) converts heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA) into "slow VISA".
    Matsuo M; Hishinuma T; Katayama Y; Hiramatsu K
    Antimicrob Agents Chemother; 2015 Jul; 59(7):4215-25. PubMed ID: 25941225
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.